Latest From PharmaLink
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2015.
Pharmalink of Sweden is basking in the "astonishingly good" Phase IIb data of Nefecon, its oral modified-release capsule of budesonide, in the treatment of primary IgA nephropathy – the most common form of glomerulonephritis. The NEFIGEN trial met its primary endpoint at a planned interim analysis and has been stopped early with respect to statistical analysis of the endpoint.
Pharmalink, a Swedish specialty company, has received orphan drug designation from the US FDA for its transplant conditioning agent Busulipo (busulfan), which the company plans to file in late 2014.
Swedish specialty pharma company Pharmalink has raised SEK196m ($15m) in a series C financing round, which the firm will spend on completing pivotal studies of its lead product Nefecon (PL-56), as well as preparing for pivotal studies of Busulipo (busulfan), and in-licensing and acquisition of cancer products.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Parent & Subsidiaries
- Senior Management
- Guido Oelkers, CEO
- Contact Info
Phone: (91) 79 4000 6300
1 Ashoknagar Bungalows
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.